Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
J Am Coll Surg. 2013 Jan;216(1):41-9. doi: 10.1016/j.jamcollsurg.2012.08.030. Epub 2012 Oct 5.
Patients undergoing liver resection for colorectal cancer liver metastasis (CRCLM) are often treated with chemotherapy before surgery. However, the associations between chemotherapy, liver injury, perioperative outcomes, and other confounding factors remain unclear. This study investigates the effect of preoperative chemotherapy for CRCLM on nontumoral liver histology and perioperative outcomes in a contemporary cohort.
Five hundred six patients underwent hepatic resection for CRCLM between April 2003 and March 2007. Histologic evaluation of nontumoral liver parenchyma for sinusoidal dilatation, steatosis, and steatohepatitis was performed in 384 cases for which tissue was available. Patient factors, tumor characteristics, chemotherapy regimens, histology of nontumoral liver, and perioperative morbidity were analyzed.
Two hundred fifty patients (65%) received preoperative chemotherapy for a median duration of 24 weeks. Irinotecan, increased body mass index (BMI), and diabetes mellitus (DM) were associated with hepatic steatosis and steatohepatitis. Sinusoidal dilatation was not associated with chemotherapy or any clinicopathologic factors. Perioperative blood transfusion was independently associated with an increased risk of any complication. Major postoperative complications were independently associated with major (≥ 3 segments) resections (57%) and perioperative blood transfusion. The use of any preoperative chemotherapy decreased the odds of major complications. Liver-related complications were independently associated with major resection and blood transfusion, but not with chemotherapy. Three postoperative deaths (0.8%) occurred, all in patients who were not treated with chemotherapy and had no evidence of liver injury.
With appropriate patient selection, liver resection for CRCLM can be safely performed in patients treated with preoperative chemotherapy.
接受结直肠癌肝转移(CRCLM)肝切除术的患者常在术前接受化疗。然而,化疗、肝损伤、围手术期结局和其他混杂因素之间的关联尚不清楚。本研究调查了在当代队列中,CRCLM 的术前化疗对非肿瘤性肝组织和围手术期结局的影响。
2003 年 4 月至 2007 年 3 月期间,506 例患者接受了肝切除术治疗 CRCLM。对 384 例有组织可供检查的患者进行了非肿瘤性肝实质的窦状扩张、脂肪变性和脂肪性肝炎的组织学评估。分析了患者因素、肿瘤特征、化疗方案、非肿瘤性肝组织学和围手术期发病率。
250 例(65%)患者接受了术前化疗,中位时间为 24 周。伊立替康、增加的体重指数(BMI)和糖尿病(DM)与肝脂肪变性和脂肪性肝炎相关。窦状扩张与化疗或任何临床病理因素均无关。围手术期输血与任何并发症的风险增加独立相关。主要术后并发症与主要(≥3 个节段)切除术和围手术期输血独立相关。任何术前化疗的使用均降低了主要并发症的几率。肝相关并发症与主要切除术和输血独立相关,但与化疗无关。3 例术后死亡(0.8%)发生,均在未接受化疗且无肝损伤证据的患者中。
在适当的患者选择下,接受术前化疗的 CRCLM 患者可安全地进行肝切除术。